[{"indications": "Indications\u00a0locally advanced prostate cancer as an\r\nalternative to surgical castration; adjuvant treatment to radiotherapy\r\nor radical prostatectomy in patients with high-risk localised or locally\r\nadvanced prostate cancer; metastatic prostate cancer; endometriosis,\r\nendometrial thinning, uterine fibroids (section 6.7.2)", "name": "LEUPRORELIN ACETATE - GONADORELIN ANALOGUES AND GONADOTROPHIN-RELEASING HORMONE ANTAGONISTS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.3 Sex hormones and hormone antagonists in malignant disease", "8.3.4 Hormone antagonists", "8.3.4.2 Gonadorelin analogues and gonadotrophin-releasing hormone antagonists", "Gonadorelin analogues", "LEUPRORELIN ACETATE"], "cautions": "Cautions\u00a0\n(From Gonadorelin analogues: British National Formulary)\nCautions\u00a0Men at risk of tumour \u2018flare\u2019 (see above) should be monitored closely during the first month of therapy. Caution is required in patients with metabolic bone disease because reduced bone mineral density can occur. The injection site should be rotated. and %s\n(From Gonadorelin analogues: British National Formulary)\nGonadorelin analogues; risk of ureteric\r\nobstruction and spinal cord compression in men", "side-effects": "Side-effects\u00a0\n(From Gonadorelin analogues: British National Formulary)\nGonadorelin analogues and %s\n(From Gonadorelin analogues: British National Formulary)\nGonadorelin analogues; also fatigue, muscle weakness,\r\nparaesthesia, hypertension, palpitation, alteration of glucose tolerance and of blood lipids; hypotension, jaundice, thrombocytopenia\r\nand leucopenia reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4835.htm", "doses": ["Name[Prostap\u00ae SR DCS (Takeda) ] prostate cancer (see indications), by subcutaneous or by intramuscular injection, 3.75\u00a0mg\r\nevery month"]}, {"indications": "Indications\u00a0see under Dose; prostate cancer (section 8.3.4.2)", "name": "LEUPRORELIN ACETATE - DRUGS AFFECTING GONADOTROPHINS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.7 Other endocrine drugs", "6.7.2 Drugs affecting gonadotrophins", "Gonadorelin analogues"], "cautions": "Cautions\u00a0\n(From Gonadorelin analogues: British National Formulary)\nCautions\u00a0Non-hormonal, barrier methods of contraception should be used during entire treatment period with gonadorelin analogues; also use with caution in patients with metabolic bone disease because decrease in bone mineral density can occur.; monitor liver function; family history\r\nof osteoporosis; chronic use of other drugs which reduce\r\nbone density including alcohol and tobacco; diabetes", "side-effects": "Side-effects\u00a0see notes above; breast tenderness; nausea, vomiting,\r\ndiarrhoea, anorexia; fever, chills; sleep disturbances, dizziness,\r\nfatigue, leucopenia, thrombocytopenia, altered blood lipids, pulmonary\r\nembolism; spinal fracture, paralysis, hypotension and worsening of\r\ndepression also reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4473.htm", "doses": ["By subcutaneous or intramuscular injection (as Prostap\u00ae SR DCS)", "Endometriosis, 3.75\u00a0mg as a single dose in first 5 days of menstrual\r\ncycle then every month for max. 6 months (course not to be repeated)", "Endometrial thinning before intra-uterine surgery, 3.75\u00a0mg as\r\na single dose (given between days 3 and 5 of menstrual cycle) 5\u20136\r\nweeks before surgery", "Reduction of size of uterine fibroids and of associated bleeding\r\nbefore surgery, 3.75\u00a0mg as a single dose every month usually for 3\u20134\r\nmonths (max. 6 months)", "By intramuscular injection (as Prostap\u00ae 3 DCS)", "Endometriosis, 11.25\u00a0mg as a single dose in first 5 days of\r\nmenstrual cycle then every 3 months for max. 6 months (course not\r\nto be repeated)"], "pregnancy": "Pregnancy\u00a0teratogenic in animal studies; see\r\nalso notes above"}, {"indications": "Indications\u00a0see under Dose; prostate cancer (section 8.3.4.2)", "name": "LEUPRORELIN ACETATE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.7 Other endocrine drugs", "6.7.2 Drugs affecting gonadotrophins", "Gonadorelin analogues"], "cautions": "Cautions\u00a0\n(From Gonadorelin analogues: British National Formulary)\nCautions\u00a0Non-hormonal, barrier methods of contraception should be used during entire treatment period with gonadorelin analogues; also use with caution in patients with metabolic bone disease because decrease in bone mineral density can occur.; monitor liver function; family history\r\nof osteoporosis; chronic use of other drugs which reduce\r\nbone density including alcohol and tobacco; diabetes", "side-effects": "Side-effects\u00a0see notes above; breast tenderness; nausea, vomiting,\r\ndiarrhoea, anorexia; fever, chills; sleep disturbances, dizziness,\r\nfatigue, leucopenia, thrombocytopenia, altered blood lipids, pulmonary\r\nembolism; spinal fracture, paralysis, hypotension and worsening of\r\ndepression also reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4473.htm", "doses": ["By subcutaneous or intramuscular injection (as Prostap\u00ae SR DCS)", "Endometriosis, 3.75\u00a0mg as a single dose in first 5 days of menstrual\r\ncycle then every month for max. 6 months (course not to be repeated)", "Endometrial thinning before intra-uterine surgery, 3.75\u00a0mg as\r\na single dose (given between days 3 and 5 of menstrual cycle) 5\u20136\r\nweeks before surgery", "Reduction of size of uterine fibroids and of associated bleeding\r\nbefore surgery, 3.75\u00a0mg as a single dose every month usually for 3\u20134\r\nmonths (max. 6 months)", "By intramuscular injection (as Prostap\u00ae 3 DCS)", "Endometriosis, 11.25\u00a0mg as a single dose in first 5 days of\r\nmenstrual cycle then every 3 months for max. 6 months (course not\r\nto be repeated)"], "pregnancy": "Pregnancy\u00a0teratogenic in animal studies; see\r\nalso notes above"}]